Ashkon Software

   







 


IMMU - Immunomedics, Inc.

Immunomedics, Inc. logo Immunomedics, Inc. (IMMU) is a biopharmaceutical company that develops monoclonal antibody-based products for the targeted treatment of cancer and other serious diseases. The company's lead product candidate, sacituzumab govitecan (IMMU-132), is currently in clinical development for the treatment of multiple types of cancer, including metastatic breast cancer, lung cancer, and bladder cancer.

In December 2020, Immunomedics was acquired by Gilead Sciences in a deal worth $21 billion. The acquisition was driven by Gilead's interest in expanding its oncology portfolio with the addition of sacituzumab govitecan, which has shown promising results in clinical trials.

Prior to the acquisition, Immunomedics had a strong pipeline of product candidates in various stages of development, including IMMU-140, which targets solid tumors, and IMMU-114, which is being developed for the treatment of non-Hodgkin lymphoma.

Immunomedics has also entered into collaborations with other biopharmaceutical companies, such as AstraZeneca, for the development and commercialization of its product candidates.

Overall, Immunomedics' focus on developing targeted cancer treatments and its acquisition by Gilead Sciences demonstrate the company's potential to make significant contributions to the biopharmaceutica

 



 

 

 
Copyright © 2000-2023, Ashkon Software LLC
Privacy Policy | Refund Policy | Disclaimer